Johnson & Johnson's coronavirus vaccine significantly increases levels of antibodies, interim data from two early-stage trials show, the company said on Wednesday.
It further added, the second dose of the single-dose vaccine results in binding antibody levels nine times higher than the levels 28 days after people received their first dose.
Several countries, including the United States, have already begun offering booster doses. The company in a release said, in anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine.